Why OptimizeRx Corporation’s (OPRX) Stock Is Up 5.62%
As of Monday, September 14, OptimizeRx Corporation’s OPRX share price has surged by 5.62%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Rosalio Madrigal
Omar Beirat
Jenna Brashear
Rosalio Madrigal
| Share Statistics | OPRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $143.5 | $298.5 | 24% |
|
| Shares Out (Mil) | 18.8 | 52.9 | 29% |
|
| Institutional Ownership | 79.9% | 79.7% | 49% |
|
| Float (Mil) | 14.5 | 44.4 | 24% |
|
| Beta | 1.05 | 1.19 | 63% |
|
| Avg Daily Volume (000s) | 124 | 458 | 37% |
|
| Price Change (52-week) |
(58.1%) | 48.7% | 14% |
|
| Growth | OPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 20.4% | 12.8% | 82% |
|
| Net Income (5yr) | 34.0% | 5.4% | 88% |
|
| EPS (5yr) | 30.6% | 15.5% | 82 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 24.3% | (15.5%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | $0.170 | $0.890 | $1.058 | |
| Month Ago EPS | $0.170 | $0.890 | $1.058 | |
| # Rev Up | 1 | 2 | 3 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.246 | $0.938 | $1.088 | |
| Year/Year Chg | (525.0%) | 229.6% | na | |
| Financials | OPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $99 | $192 | 26% |
|
| Net Income (TTM) (Mil) | $5 | ($9) | 43% |
|
| EPS (TTM) | $0.246 | ($0.500) | 48% |
|
| Operating Cash Flow (TTM) (Mil) | $18 | $9 | 40% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $3 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $18 | $16 | 32% |
|
| Enterprise Value (Q1) (Mil) | $160 | $233 | 24% |
|
| Valuation | OPRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.09 | 1.29 | 25% |
|
| P/E | 31.0 | 40.3 | 72% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.0 | 2.4 | 47% |
|
| Ratios | OPRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 73.2% | 61.6% | 83% |
|
| Net Margin | 4.7% | (22.6%) | 47% |
|
| ROA | 2.8% | (17.9%) | 60% |
|
| ROE | 3.7% | (2.1%) | 41% |
|
| Liabilities to Assets | 20.2% | 31.9% | 13% |
|
| F-Score | 7 | 4 | 82% |
|
OptimizeRx Corporation did not pass any screens on 9/22/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors